Tim Rothwell


Timothy G. Rothwell has been the Chairman of Emisphere Technologies Inc. (OTC: EMIS), since early 2012 and prior to that a Director of the Company from late 2009. Mr. Rothwell is also the Chairman of Speracura LLC, a healthcare consulting company from 2009 and the President of the SDHB PHEOPARA Coalition from 2016.

Mr. Rothwell was formerly Chairman of Sanofi from February 2007 to October 2009 in the U.S.  He also served as Chief Executive Officer and President of Sanofi-Aventis from September 2004 to February 2007. Mr. Rothwell oversaw all domestic commercial operations as well as the coordination of Industrial Affairs and Research and Development activities in the U.S.  From May 2003 to September 2004, Mr. Rothwell was President and Chief Executive Officer of Sanofi-Synthelabo, Inc. and was instrumental in the formation of Sanofi-Aventis U.S. in 2004. Prior to that, from January 1998 to May 2003, he served in various capacities at Pharmacia, including as President of the company’s Global Prescription Business. From January 1995 to January 1998, Mr. Rothwell also served as worldwide President of Rhone-Poulenc Rorer Pharmaceuticals and President of the company’s Global Pharmaceutical Operations. In his long career, Mr. Rothwell has also served as Chief Executive Officer of Sandoz Pharmaceuticals, Vice President of Global Marketing and Sales at Burroughs Wellcome, and Senior Vice President of Marketing and Sales for the U.S. for Squibb Corporation which later became a Division of Bristol-Myers Squibb.

Mr. Rothwell holds a Bachelor of Arts from Drew University and earned his J.D. from Seton Hall University.

He formerly served on the PhRMA Board of Directors, as well as the Institute of Medicine’s Evidence-Based Medicine roundtable, the CEO Roundtable on Cancer, the Healthcare Businesswoman’s Association Advisory Board, the Board of Trustees for the Somerset Medical Center Foundation, the Board of Trustees for the HealthCare Institute of New Jersey, as a Trustee of the Corporate Council for America’s Children at the Children’s Health Fund, the Board of Directors of Agenus (NASDAQ: AGEN), the Board of Directors of Akrimax Pharmaceuticals LLC, Chairman of the Board of Directors of Archimedes Pharma LLC , Chairman of the Board of Directors of New American Therapeutics, and a member of the Board of Visitors for Seton Hall Law school.

He also served as the Chairman of the Pheo Para Alliance from 2009 to 2014 which is a non-profit organization dedicated to helping patients who suffer from pheochromocytoma and paraganglioma.

« Back